Preferred Name |
Bortezomib |
|
Synonyms |
[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid BORTEZOMIB Bortezomib LDP 341 MLN341 PS-341 PS341 Velcade bortezomib velcade |
|
Definitions |
A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy. |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1851 |
|
Accepted_Therapeutic_Use_For |
Multiple Myeloma; Advanced Thyroid Cancer |
|
ALT_DEFINITION |
A drug used to treat multiple myeloma. It is also used to treat mantle cell lymphoma in patients who have already received at least one other type of treatment and is being studied in the treatment of other types of cancer. Bortezomib blocks several molecular pathways in a cell and may cause cancer cells to die. It is a type of proteasome inhibitor and a type of dipeptidyl boronic acid. |
|
CAS_Registry |
179324-69-7 |
|
CHEBI_ID |
CHEBI:52717 |
|
Chemical_Formula |
C19H25BN4O4 |
|
code |
C1851 |
|
Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173234 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C174019 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
Contributing_Source |
CTRP FDA GDC HemOnc PCDC |
|
DEFINITION |
A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy. |
|
Display_Name |
Bortezomib |
|
FDA_UNII_Code |
69G8BD63PP |
|
FULL_SYN |
[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid BORTEZOMIB Bortezomib LDP 341 MLN341 PS-341 PS341 Velcade bortezomib velcade |
|
Has_Target | ||
Is_PCDC_AML_Authorized_Value_For_Variable | ||
Is_Value_For_GDC_Property | ||
label |
Bortezomib |
|
Legacy Concept Name |
Bortezomib |
|
Maps_To |
Bortezomib |
|
NCI_Drug_Dictionary_ID |
43560 |
|
NSC Number |
681239 |
|
PDQ_Closed_Trial_Search_ID |
43560 |
|
PDQ_Open_Trial_Search_ID |
43560 |
|
Preferred_Name |
Bortezomib |
|
prefixIRI |
Thesaurus:C1851 |
|
Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
UMLS_CUI |
C1176309 |
|
subClassOf |